Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYAD
Previous Symbol
CUSIPN/A
Phone321-039-4100
Debt
Debt-to-Equity Ratio0.01
Current Ratio6.61
Quick RatioN/A
Price-To-Earnings
Trailing P/E Ratio-7.84
Forward P/E Ratio-7.13
P/E GrowthN/A
Sales & Book Value
Annual Sales$4 million
Price / Sales68.47
Cash FlowN/A
Price / CashN/A
Book Value$5.44 per share
Price / Book5.10
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees87
Outstanding Shares9,870,000
Market Cap$274.95 million
OptionableNot Optionable
CELYAD SA/ADR (NASDAQ:CYAD) Frequently Asked Questions
What is CELYAD SA/ADR's stock symbol?
CELYAD SA/ADR trades on the NASDAQ under the ticker symbol "CYAD."
What price target have analysts set for CYAD?
5 Wall Street analysts have issued 1-year target prices for CELYAD SA/ADR's stock. Their forecasts range from $44.00 to $51.00. On average, they anticipate CELYAD SA/ADR's stock price to reach $47.50 in the next twelve months. This suggests a possible upside of 71.2% from the stock's current price. View Analyst Price Targets for CELYAD SA/ADR.
What is the consensus analysts' recommendation for CELYAD SA/ADR?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CELYAD SA/ADR in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CELYAD SA/ADR.
What are Wall Street analysts saying about CELYAD SA/ADR stock?
Here are some recent quotes from research analysts about CELYAD SA/ADR stock:
- 1. HC Wainwright analysts commented, "We base our $46 price target on probability-adjusted revenue forecasts for CYAD-01 in r/r AML and third line metastatic CRC. We use the net present value of our revenue forecast through 2026, apply a 25% POS for AML and 20% POS for CRC, a 4x price/sales multiple. We include our year-end 2018 estimated fully diluted net cash of $4.39/share (assuming €1.00 = $1.15) to arrive at our price target. Our P/S multiple of 4x is in-line with Celyad’s peers that range between 2-5x. We use a 25% discount rate for the pipeline due to development risks and note that it is at the high end of the typical range of 15-25% for products in development. We project revenues of $239M for CYAD-01 in AML and $596M for CRC in 2026." (11/12/2018)
- 2. William Blair analysts commented, "Celyad S.A. Using the Body’s “Natural Born Killers” in Solid and Liquid Tumors; Initiating With an Outperform Rating We are initiating coverage on Celyad with an Outperform rating and $53 fair value estimate." (10/30/2018)
- 3. According to Zacks Investment Research, "Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. " (10/24/2018)
Has CELYAD SA/ADR been receiving favorable news coverage?
News articles about CYAD stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. CELYAD SA/ADR earned a media sentiment score of 1.9 on InfoTrie's scale. They also gave media stories about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are some of CELYAD SA/ADR's key competitors?
Some companies that are related to CELYAD SA/ADR include Retrophin (RTRX), Intra-Cellular Therapies (ITCI), Amphastar Pharmaceuticals (AMPH), Zai Lab (ZLAB), Rhythm Pharmaceuticals (RYTM), Kiniksa Pharmaceuticals (KNSA), Alder Biopharmaceuticals (ALDR), Uniqure (QURE), Lexicon Pharmaceuticals (LXRX), Aptinyx (APTX), Akorn (AKRX), Puma Biotechnology (PBYI), ImmunoGen (IMGN), Dicerna Pharmaceuticals (DRNA) and Viking Therapeutics (VKTX).
Who are CELYAD SA/ADR's key executives?
CELYAD SA/ADR's management team includes the folowing people:
- Mr. Michel E. Lussier, Co-Founder & Chairman (Age 62)
- Dr. Christian Homsy M.D., MBA, CEO & Exec. Director (Age 60)
- Mr. Filippo Joseph Petti, Chief Financial Officer
- Dr. Jean-Pierre Latere, Chief Operating Officer (Age 43)
- Nicolas Van Hoecke, Director of Investor Relations & Communications
When did CELYAD SA/ADR IPO?
(CYAD) raised $99 million in an initial public offering on Friday, June 19th 2015. The company issued 1,400,000 shares at $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.
Who are CELYAD SA/ADR's major shareholders?
CELYAD SA/ADR's stock is owned by many different of institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (6.29%) and Wells Fargo & Company MN (0.06%).
Which institutional investors are buying CELYAD SA/ADR stock?
CYAD stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc. and Wells Fargo & Company MN.
How do I buy shares of CELYAD SA/ADR?
Shares of CYAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CELYAD SA/ADR's stock price today?
One share of CYAD stock can currently be purchased for approximately $27.75.
How big of a company is CELYAD SA/ADR?
CELYAD SA/ADR has a market capitalization of $274.95 million and generates $4 million in revenue each year. The company earns $-63,740,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis. CELYAD SA/ADR employs 87 workers across the globe.
What is CELYAD SA/ADR's official website?
How can I contact CELYAD SA/ADR?
CELYAD SA/ADR's mailing address is RUE EDOUARD BELIN 2, MONT-SAINT-GUIBERT C9, 1435. The company can be reached via phone at 321-039-4100.
MarketBeat Community Rating for CELYAD SA/ADR (NASDAQ CYAD)
MarketBeat's community ratings are surveys of what our community members think about CELYAD SA/ADR and other stocks. Vote "Outperform" if you believe CYAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
